Date:11/7/2012

gy.  In August 2012, Fanapt™ was granted market approval in Israel for the treatment of schizophrenia.  In November 2012, Vanda was notified by its distribution partner, Biotoscana Farma S.A., that Fanapt™ had been granted market approval in Argentina for the treatment of schizophrenia.Vanda recorded third quarter 2012 revenue of $8.3 million including Fanapt® royalties of $1.5 million.  Fanapt® prescriptions, as reported by IMS, were approximately 38,500 for the third quarter of 2012.  This represents a 3% increase over second quarter 2012 prescriptions and a 15% increase over third quarter 2011 prescriptions.  In October 2012, Novartis discontinued development of the long-acting injectable formulation of iloperidone.  Vanda has the right to develop and commercialize all formulations of iloperidone in markets outside the United States and Canada. CONFERENCE CALL
Vanda has scheduled a conference call for today, Wednesday, November 7, 2012, at 10:00 AM ET.  During the call, Vanda's management will discuss the third quarter 2012 results and other corporate activities.  Investors can call 800-299-7089 (domestic) and 617-801-9714 (international) and use passcode 66514556.  A replay of the call will be available beginning Wednesday, November 7, 2012 at 12:00 PM ET and will be accessible until Wednesday, November 14, 2012, at 5:00 PM ET.  The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers.  The access number is 34968750.

The conference call will be broadcast simultaneously on Vanda's website, http://www.vandapharma.com.   Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations.  The call will also be archived on Vanda's website for a period of
'/>"/>

SOURCE Vanda Pharmaceuticals Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
2. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
3. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
4. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
5. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
6. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
7. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
8. Vanda Pharmaceuticals Reports First Quarter 2012 Results
9. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
11. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering